Cardiogenic shock is a state of inadequate systemic tissue perfusion, despite adequate left ventricular filling pressure. It is caused by extensive myocardial damage and appears to be aggravated by a systemic inflammatory response \[[@B1]-[@B4]\]. The result is hypotension with metabolic acidosis and often a fatal outcome. The condition affects approximately 5% of the patients with myocardial infarction, and carries a dismal prognosis if it prevails after reperfusion.

Therapeutic hypothermia has several properties of potential benefit in cardiogenic shock: Experiments with isolated myofibrils, papillary muscles and cross-circulated hearts have demonstrated that mild hypothermia increases myocardial contractility \[[@B5]-[@B7]\]. In the *in vivo*heart, mild hypothermia has been found to increase stroke volume and cardiac output \[[@B6],[@B8]\].

The increase in contractility is considered to be mediated by an increased myofilament sensitivity to existing Ca^2+^, without a corresponding increase in myocardial oxygen consumption \[[@B9]\]. Moreover, hypothermia reduces the metabolic rate with 5 to 7%/°C \[[@B10],[@B11]\], thereby reducing the demand on the circulation from the peripheral tissues. In an experimental setting, it also has the ability to reduce infarct size if applied prior to reperfusion \[[@B12],[@B13]\].

In dog-based and porcine-based models of cardiogenic shock secondary to ischemia, therapeutic hypothermia has improved hemodynamic and metabolic parameters, and reduced mortality \[[@B14],[@B15]\]. No randomized controlled trials of therapeutic hypothermia in cardiogenic shock in humans exist, but case series indicate that the effects observed in animal experiments can be reproduced \[[@B16]-[@B19]\].

In conclusion, therapeutic hypothermia is a promising treatment option for patients in cardiogenic shock that warrants further investigation.
